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tract. The importance of assessing ongoing GI mucosal inflam-
mation in this condition lies in the fact that it helps predict 
course of disease,1-7 response to therapy,1 advent of complica-
tions,7 need for hospitalization and surgery.4 To this effect, var-
ious studies have shown mucosal healing to be the best pre-
dictor of positive long-term outcomes.3-6 Endoscopy is cur-
rently regarded as the gold standard test for assessment of 
mucosal healing.8 However, it is expensive, invasive, associat-
ed with patient discomfort and has an associated small risk of 
serious complications, thus making it an unfeasible modality 
for frequent monitoring. Biochemical markers like CRP are in-
expensive but have moderate diagnostic accuracy with a 
specificity of 0.92 (95% CI, 0.72–0.96) but a sensitivity of only 
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Fecal calprotectin (FC) is a highly sensitive disease activity biomarker in inflammatory bowel disease. However, there are con-
flicting reports on whether the diagnostic accuracy in Crohn’s disease is influenced by disease location. The aim of this study was 
to undertake a systematic review of the published literature. Relevant databases were searched from inception to November 8, 
2016 for cohort and case control studies which had data on FC in patients with isolated small bowel (SB) and large bowel (LB) 
Crohn’s disease. Reference standards for disease activity were endoscopy, magnetic resonance imaging, computed tomography 
or a combination of these. The QUADAS-2 research tool was used to assess the risk of bias. There were 5,619 records identified 
at initial search. The 2,098 duplicates were removed and 3,521 records screened. Sixty-one full text articles were assessed for 
eligibility and 16 studies were included in the final review with sensitivities and specificities per disease location available from 8 
studies. Sensitivities of FC at SB and LB locations ranged from 42.9% to 100% and 66.7% to 100% respectively while correspond-
ing specificities were 50% to 100% and 28.6% to 100% respectively. The sensitivities and specificities of FC to accurately measure 
disease activity in Crohn’s disease at different disease locations are diverse and no firm conclusion can be made. Better studies 
need to be undertaken to categorically answer the effect of disease location on the diagnostic accuracy of FC. (Intest Res, Pub-
lished online )
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REVIEW ARTICLE
INTRODUCTION
Crohn’s disease (CD) is a chronic disorder characterized by 
transmural inflammation and patchy distribution in the GI 
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0.49 (95% CI, 0.34–0.64),9 hence limiting its use as a disease 
biomarker. 
Since the acutely inflamed intestinal mucosa is deemed to 
be neutrophil–rich, fecal tests based on neutrophil-derived 
markers are a realistic option for assessing mucosal inflam-
mation. Among the various fecal markers of intestinal inflam-
mation; fecal calprotectin (FC) is the one most commonly 
used in clinical practice.10 FC has a sensitivity of 87% and 
specificity of 67% when used to detect endoscopic activity in 
symptomatic CD.9 It accurately predicts the response to thera-
py as well as 1-year risk of relapse.11-13 There are though con-
flicting reports on whether the diagnostic accuracy in CD is 
influenced by disease location. FC has been shown to have a 
lower specificity in CD than in UC and this might be driven 
through the different disease locations.14-16 Some studies re-
port that the FC level is lower in small bowel (SB) disease lo-
cation compared to large bowel (LB) location,17,18 while others 
did not observe any difference.14,19 We feel this is an important 
matter that could potentially either change practice or serve 
as a basis for downstream research. We thus aimed to under-
take a systematic review of published literature and discuss 
the effect of disease location on the sensitivity and specificity 
of FC to accurately measure disease activity in CD. 
METHODS
1. Criteria for Inclusion and Exclusion
Case control and cohort studies that provided data on FC sep-
arately by SB and LB locations were selected. Only those stud-
ies which had clearly mentioned the use of endoscopy, MRI, 
CT or a combination of these modalities as reference standard 
to assess disease activity were included.8,20 The subjects in-
cluded both adult and pediatric patients who had been diag-
nosed with CD on the basis of their clinical symptoms and 
supporting investigations (endoscopy, biopsies, imaging, 
blood and stool tests). We also included studies in which 
healthy volunteers and subjects with irritable bowel syndrome 
were recruited as controls. We excluded studies focusing only 
on SB-CD and studies where the reference standard for activi-
ty used was based on clinical or biochemical criteria. We also 
excluded studies specifically dealing with postoperative CD as 
it would not have been possible to define the disease location 
as SB or LB if the recurrence was limited to the anastomosis. 
2. Search Strategy
Our search included Medline, Embase, Web of Science and 
Cochrane Library from inception up to November 8, 2016 
with the help of a senior librarian to obtain the appropriate 
studies. There were no language or publication restrictions ap-
plied while searching. Details of the search strategy are pro-
vided in the Supplementary Material 1.
Conference proceedings from Digestive Diseases Week, 
United European Gastroenterology Week, European Crohn’s 
and Colitis Organisation (ECCO) and British Society of Gastro-
enterology annual meetings over the past 12 years (2005–2016) 
were also searched for relevant additional studies. We per-
formed a manual search from references in the included stud-
ies and pertinent review articles. We also searched the Grey Lit-
erature Database OpenGrey to check for eligible studies.
3. Selection
The selected studies were initially screened for eligibility by 3 
authors (E.G.S., R.W., and A.A.T.). The abstracts were reviewed 
and those eligible were included for full text review. The full 
manuscripts were independently assessed (E.G.S. and G.
W.M.) as per the inclusion criteria. If there were any disagree-
ments, these were resolved by discussion and consensus with 
the other authors (S.S., R.W., and A.A.T.). Studies published 
only in abstract format were included as long as inclusion cri-
teria were satisfied.
4. Data Extraction
Two authors (E.G.S. and G.W.M.) independently completed 
the data extraction forms for studies in the final selection list. 
The following data was collated: general information (journal, 
year, author, title), publication type (full paper or abstract), lo-
cation, number of centers involved, study design (prospective/ 
cross-sectional), total number of CD subjects and stratifica-
tion based on disease location, age group (adult/pediatric/
both), follow up period in months, FC levels with cutoff, clini-
cal disease activity index, relevant reference standard (with 
appropriate disease activity score if provided), number of true 
positives (TP), true negatives (TN), false positives (FP) and 
false negatives (FN) and miscellaneous details. If any of the 
selected studies had missing data or needed clarification, 
multiple attempts through electronic mail were made to con-
tact the authors to furnish the same.
5. Risk of Bias
To assess the risk of bias, QUADAS-2 was used (Supplementa-
ry Material 2). This is a research tool to check the quality of 
systematic reviews of diagnostic accuracy studies.21 This was 
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assessed independently by 2 authors (E.G.S. and G.W.M.) 
while any disagreement was resolved by consensus with co-
authors (S.S., R.W., and A.A.T.).
6. Data Synthesis
Sensitivity and specificity in the SB and LB locations were 
separately derived by calculation from the information pro-
vided (i.e., TP, TN, FP, and FN) or as reported in the published 
literature. 
RESULTS
The electronic data base search on November 8, 2016 identi-
fied 5,619 results. After the removal of 2,098 duplicates, 3,521 
records were screened for inclusion. From the latter, 61 studies 
were deemed to be relevant and subjected to full text review. 
Thereafter, 45 studies12,13,15,22-63 were excluded either because 
the numerical data on FC at SB and LB locations were not sep-
arately available or because the reference standards used did 
not conform to inclusion criteria. Finally, 16 studies were in-
cluded in the qualitative review (Fig. 1) involving 328 patients 
with SB-CD and 332 patients with LB disease location.
Fig. 1. PRISMA flow diagram. aSixteen studies, numerical data not 
available for fecal calprotectin (FC) at large bowel and small bowel 
locations separately; 16 studies, reference standards for assess-
ment of disease activity were different from those mentioned in 
inclusion criteria; 13 studies, both numerical data for FC at the 2 
locations were not separately available and reference standards 
used for assessment of disease activity were different from those 
mentioned in inclusion criteria. PRISMA, Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses.
5,619 Records identified by 
database searching
3,521 Records screened for 
inclusion
61 Full text articles assessed 
for eligibility
16 Studies included in 
qualitative analysis
2,098 Duplicates removed
3,460 Records excluded
45 Full text articles excluded, 
with reasonsa
Table 1. Study Characteristics       
Study Design Patient spectrum SB Crohn's LB Crohn's Reference standard/scoring system used
af Björkesten14 Prospective Anti-TNF treated luminal Crohn’s 33 50 SES-CD
Faubion65 Cross-sectional Crohn’s cohort on follow-up 22 12 ICO-CTE score
Gecse17 Cross-sectional Crohn’s undergoing ileocolonoscopy 9 20 SES-CD
Jensen19 Cross-sectional Suspected Crohn’s under evaluation 13 16 Endoscopy/capsule/surgery
Jones64 Cross-sectional Crohn’s undergoing ileocolonoscopy 53 40 SES-CD
Lobatón67 Cross-sectional Crohn’s undergoing ileocolonoscopy 26 45 CDEIS
Makanyanga68 Cross-sectional Crohn’s cohort on follow-up 18 15 MEGS 
Maltz69 Cross-sectional Crohn’s cohort on follow-up 9 18 Endoscopy
Schoepfer70 Cross-sectional Crohn’s undergoing ileocolonoscopy 35 20 SES-CD
Sipponen71 Cross-sectional Crohn’s undergoing ileocolonoscopy 16 17 SES-CD
Sipponen18 Cross-sectional Crohn’s undergoing ileocolonoscopy 19 14 CDEIS
Stawczyk-Eder72 Cross-sectional Hospitalized Crohn’s 44 22 SES-CD
Zittan73 Cross-sectional Crohn’s cohort on follow-up 14 23 SES-CD, MaRIA
Moniuszko74 Cross-sectional Hospitalized Crohn’s NA NA SES-CD, CT enteroclysis
Goutorbe75 Cross-sectional Crohn’s undergoing ileocolonoscopy 13 12 CDEIS
Lin76 Prospective Crohn’s cohort on follow-up 4 8 CDEIS
SB, small bowel; LB, large bowel; SES-CD, Simple Endoscopic Score for Crohn’s Disease; ICO-CTE, ileocolonoscopy and CT enterography; CDEIS, Crohn’s 
Disease Endoscopic Index of Severity; MEGS, MRI enterography global score; MaRIA, magnetic resonance index of activity; NA, not available. 
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1. Study Demographics
Fourteen relevant cross-sectional17,19,64-75 and 2 prospective 
studies14,76 were published between 2008 and 2016 (Table 1). 
Four of the 16 studies were published as conference ab-
stracts65,69,73,74 although 1 of these was subsequently published 
as a full text article.66 Almost all the studies were single/dual-
center based other than the studies by Faubion et al.66 and Lin 
et al.76 which were multi-center. All the studies were per-
formed in Europe and North America apart from a single 
study originating from Asia.76 The majority of the studies in-
volved adult subjects. The study by Jones et al.64 included 23 
subjects who were less than 16 years while the youngest sub-
ject in the study by Jensen et al.19 was 16 years. With regard to 
the reference standards utilized; 11 studies used endoscopy, 2 
used endoscopy and CT in combination while there was one 
each for MRI alone, endoscopy and MRI in combination and 
a composite assessment of endoscopy/capsule endoscopy/
surgery (Table 1).
2. Risk of Bias Assessment
With regard to QUADAS-2 risk assessments of the selected 
studies (Table 2), only a single study75 scored low in all 4 do-
mains of risk of bias and the domain of concern for applicabil-
ity. There were again just 3 studies64,71,76 by which scored low 
in 3 domains of risk of bias. Most studies had an unclear risk of 
bias in patient selection. With respect to the index test, there 
were 3 studies that had high risk67,68,72 while one69 was unclear. 
The studies were almost evenly distributed between low and 
unclear risk with regard to the reference standard. Eight stud-
ies had either high or unclear risk of bias under subject flow 
and selection.18,64,66-68,70,73,74 There were just 6 studies64,67,70,72,75,76 
which had low concern for applicability under subject selec-
tion. 
3. Sensitivity and Specificity of FC by Location
The data on the effect of disease location on FC is heteroge-
neous (Table 3). Some studies17,18,67,69 showed that the FC was 
significantly higher in LB vs SB location while others14,19,68,70,74-76 
did not corroborate this finding, though absolute values have 
limited value. 
The studies by Jones et al.,64 Sipponen et al.71, and Zittan et 
al.73 showed that FC significantly correlated with the reference 
standard only at the LB location but not at the SB location while 
the other 2 studies67,72 showed that FC correlated with the ref-
erence standard at both the locations (Table 4). The reference 
standard used in these studies was endoscopy with the scor-
Table 2. QUADAS-2 Risk Assessment for the Selected Studies       
Study
Risk of bias Applicability concerns
Subject 
selection
Index 
test
Reference 
standard
Flow and 
timing
Subject 
selection
Index 
test
Reference 
standard
af Björkesten14 Low Low Low Low High NC NC
Faubion66 Unclear Low Unclear Unclear High NC NC
Gecse17 High Low Unclear Low Unclear NC NC
Jensen19 Unclear Low Unclear High High NC NC
Jones64 Unclear Low Low Low Low NC NC
Lobatón67 Low High Low High Low NC NC
Makanyanga68 Unclear High Low Unclear High NC NC
Maltz69 Unclear Unclear Unclear Low Unclear NC NC
Schoepfer70 High Low Low Unclear Low NC NC
Sipponen71 Unclear Low Low Low Unclear NC NC
Sipponen18 Unclear Low Unclear Unclear Unclear NC NC
Stawczyk-Eder72 Unclear High Low Low Low NC NC
Zittan73 Unclear Low Unclear Unclear Unclear NC NC
Moniuszko74 Unclear Low Unclear Unclear Unclear NC NC
Goutorbe75 Low Low Low Low Low NC NC
Lin76 Unclear Low Low Low Low NC NC
NC, not a concern. 
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Table 3. Comparison of Mean or Median Levels in the 2 Locations        
Study SB Crohn’s
LB 
Crohn’s
Reference standard/
scoring system used Key result Inference
af Björkesten14 33 50 SES-CD Median FC level in SB: 86 µg/g
LB: 158 µg/g (NS)
No difference between both locations
Gecse17 9 20 SES-CD Mean FC level in SB: 297±81 mg/g
LB: 1,523±97 mg/g (P<0.0001)
Higher in LB location
Jensen19 13 16 Endoscopy/capsule/surgery Median FC level in SB: 890 mg/kg
LB: 830 mg/kg (NS)
No difference between both locations
Lobatón67 26 45 CDEIS Median FC level in SB: 420.5 µg/g
LB: 1,297 µg/g (P=0.013)
Higher in LB location
Makanyanga68 18 15 MEGS Mean FC level in SB: 319.1 µg/g
LB: 342 µg/g (NS)
No difference between both locations
Maltz69 9 18 Endoscopy Median FC level in SB: 442 µg/g
LB: 66 µg/g (P<0.002)
Higher in LB location
Schoepfer70 35 20 SES-CD Mean FC level in SB: 287±279 µg/g
LB: 401±312 µg/g (NS)
No difference between both locations
Sipponen18 19 14 CDEIS Median FC level in SB: 180 µg/g
LB: 1,383 µg/g (P=0.017)
Higher in LB location
Moniuszko74 NA NA SES-CD, CT enteroclysis Median FC level in SB: 195 µg/g
LB: 401 µg/g (NS)
No difference between both locations
Goutorbe75 13 12 CDEIS Median FC level in SB: 841 µg/g
LB: 1,575.5 µg/g (NS)
No difference between both locations
Lin76 4 8 CDEIS Median FC level in SB: 2,693 µg/g
LB: 176 µg/g (NS)
No difference between both locations
SB, small bowel; LB, large bowel; SES-CD, Simple Endoscopic Score for Crohn’s Disease; FC, fecal calprotectin; CDEIS, Crohn’s Disease Endoscopic Index of 
Severity; MEGS, MRI enterography global score; NA, not available.
Table 4. Correlation between Fecal Calprotectin and Reference Standard at Respective Locations   
Study SB Crohn’s LB Crohn’s Reference standard/scoring system used Key result Comment
Jones64 53 40 SES-CD Correlation in
SB: -0.01 (NS)
LB: 0.8 (P<0.05)
Correlation noted only at LB location
Lobatón67 26 45 CDEIS Correlation in
SB: 0.437 (P=0.016)
LB: 0.725 (P<0.01)
-
Sipponen71 16 17 SES-CD Correlation in
SB: 0.317 (NS)
LB: 0.642 (P<0.01)
Correlation noted only at LB location
Stawczyk-Eder72 44 22 SES-CD Correlation with SES-CD in
SB: 0.78 (P<0.0001)
LB: 0.78 (P<0.0002)
-
Zittan73 14 23 SES-CD, MaRIA Correlation in
SB: 0.4 (P=NS)
LB: 0.61 (P<0.0001)
Correlation noted only at LB location
SB, small bowel; LB, large bowel; SES-CD, Simple Endoscopic Score for Crohn’s Disease; CDEIS, Crohn’s Disease Endoscopic Index of Severity; MaRIA, 
magnetic resonance index of activity. 
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ing system being either Simple Endoscopic Score for Crohn’s 
Disease (SES-CD),64,71-73 Crohn’s Disease Endoscopic Index of 
Severity (CDEIS)67 although in the study by Zittan et al.,73 MR 
enterography score (MaRIA, magnetic resonance index of ac-
tivity) was also used in the SB location.
The sensitivity and specificity data were available for 8 stud-
ies in total (Table 5). Sensitivities were available in the pub-
lished literature for just 2 studies19,67 while in 1 study,73 these 
were retrospectively provided by the author. For the remain-
ing 5 studies,14,17,66,74,75 the relevant authors provided the raw 
data on the number of TP, TN, FP and FN, from which the sen-
sitivity and specificity values were retrospectively calculated.
Including data from all the 8 studies, the sensitivity and 
specificity of FC in the SB ranged from 42.9% to 100% and 
from 50% to 100% respectively. The sensitivity and specificity 
of FC in the LB ranged from 66.7% to 100% and from 28.6% to 
100% respectively.
DISCUSSION
A variety of clinical studies have indicated a wide range of sen-
sitivities and specificities for FC in CD at different disease lo-
cations.14,17-19 We have undertaken a systematic review to ob-
jectively appraise the literature. Overall, the sensitivity and 
specificity of FC in the SB ranged from 42.9% to 100% and 50% 
to 100% while those in the LB were from 66.7% to 100% and 
28.6% to 100% respectively indicating that FC may be equally 
useful to measure disease activity in CD at these 2 locations 
but no firm conclusion can be made from the published litera-
ture. The QUADAS -2 tool indicated that the quality of the se-
lected studies was modest. 
The data represented here is heterogeneous with varying 
gold-standards. There are only 5 studies in the published litera-
ture with the primary aim of investigating the effect of disease 
location on the sensitivity and specificity of FC.17,19,72-74 In the 
remaining eleven studies, this information was expressed as a 
sub-analysis. Moreover, apart from the published data, raw 
data to calculate sensitivity and specificity was only available 
in 5 small studies. These data did not pertain to all the cohorts 
published but only relevant to smaller sub-groups.14,17,65,74,75 
One might speculate that LB disease location is within reach 
of colonoscopy and hence is more commonly validated with a 
gold-standard investigation. As for SB disease location, unless 
the disease is in the terminal ileum this might not be as accu-
rately located though the sensitivities and specificities of MRI 
to measure disease activity is widely published.77 A possible 
reason for the effect of disease location on the specificity of FC 
might be that other common disease of the colon such as di-
verticulitis, microscopic colitis or infectious enteritides might 
raise FC other than LB-CD. The same might not be said for SB 
inflammation in cohort studies undertaken in the Western 
Hemisphere where CD is the commonest cause for ileal in-
flammation. Effectively, this systematic analysis highlights the 
need of properly designed prospective studies to answer this 
important question.
Despite endoscopy being the gold standard for assessment 
of disease activity, we also included studies where radiological 
tests such as CT or MRI were utilized as reference standards 
to evaluate the SB activity as these have been supported by 
the ECCO guidelines.8,20 However, the lack of a uniform gold 
standard was a limiting factor. This heterogeneity multiplied 
by the inter-observer variability for the various investigative 
Table 5. Diagnostic Accuracy of Fecal Calprotectin in CD at SB versus LB Location 
Study
Sensitivity Specificity FC cutoff 
(µg/g)SB (95% CI) LB (95% CI) SB (95% CI) LB (95% CI)
Jensen19,a 92 94 NA NA 50
Lobatón67,a 63 79 100 100 272
Zittan79,a 75 100 50 67 100
af Björkesten14 60.0 (32.9–82.5) 78.9 (53.9–93) 100 (31.0–100) 75.0 (35.6–95.5) 100
Faubion66 76.9 (46.0–93.8) 80.0 (29.9–98.9) 75.0 (35.6–95.5) 28.6 (5.1–69.7) 100
Gecse17 42.9 (11.8–79.8) 100 (78.1–100) NA 100 (5.5–100) 200
Goutorbe75 100 (51.7–100) 100 (62.9–100) 50.0 (13.9–86.0) 33.3 (1.8–87.5) 200
Moniuszko74 100 (31.0–100) 66.7 (30.9–91.0) 100 (31.0–100) 50.0 (2.7–97.3) 238
All unit of data is percent.
aRaw data and associated CI are not available.       
SB, small bowel; LB, large bowel; FC, fecal calprotectin; NA, not available.  
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modalities used, limited the validity of the reported sensitivi-
ties and specificities. The limitations of CT and MRI may in-
clude decreased sensitivity to detect early disease that may 
otherwise be detected on endoscopy. Even in those studies 
that have used endoscopy as the reference standard, various 
scoring systems such as the SES-CD and the CDEIS scores 
were utilized. These scoring systems themselves have limita-
tions such as the endoscopic evaluation being confined to the 
terminal ileum or colon subject to the reach of the colono-
scope and inter-observer variability. Capsule endoscopy is a 
non-invasive way to evaluate the entire SB. However, its disad-
vantages include lack of utility when there is a SB stricture as 
well as subjective nature of reporting.
There are certain limitations in the published literature that 
need to be highlighted. The FC cutoffs used in all the reported 
studies are different. The cutoff values can influence the test 
accuracy and there are different cutoff values for FC depend-
ing on the intent of use. The current National Institute for 
Health and Care Excellence (NICE) guideline78 indicates that 
an FC value < 50 μg/g suggest no significant GI mucosal in-
flammation, with a value of > 250 μg/g corresponds well with 
endoscopic and histology activity.9,79 The cutoff values used in 
the studies presented in this systematic review were not uni-
form. Most of the studies used cutoff of 100 μg/g with just 3 
studies using a cutoff value of 50 μg/g. The diagnostic test used 
to determine the FC levels were not uniform. Most studies 
used ELISA test while some used the rapid test (Quantum 
Blue). Stool collection time was not standardized across the 
studies described in this systematic review. There was a pauci-
ty of detail regarding processing of the stool samples across 
the studies. These factors could also contribute to differences 
of FC across the studies. 
Our systematic review included both pediatric and adult 
studies though most of the data was from the adult population 
and the pediatric population appeared under-represented. 
The specificity of FC appears to improve with patient age. van 
Rheenen et al.,80 in their meta-analysis of 13 studies, obtained 
a pooled sensitivity of 93% and specificity of 96% in adults and 
92% and 76% in children respectively. The larger share of irri-
table bowel disease with absence of alarm symptoms was 
thought to overestimate the specificity in the adults subjects 
compared to children. Henderson et al.54 undertook a meta-
analysis of 8 studies and concluded that the sensitivity and 
specificity of FC in IBD in the pediatric cohort were 97.8% and 
68.2%. Factors that could contribute to the difference in speci-
ficity of FC in adult versus pediatric populations include the 
variation in the disease prevalence and spectrum, variation in 
the FC threshold to trigger endoscopic evaluation, parental 
expectation and concerns about missed diagnosis.54 The pedi-
atric cohort in this systematic review was too small to be able 
to make any firm conclusions. 
We observed that most of the studies originated from the 
Western Hemisphere except for the study from Taiwan,76 per-
haps indicating that these findings may not be reflective of the 
situation in the general population worldwide. It would be dif-
ficult to get homogenous world-wide data on the accuracy of 
FC in SB and LB locations due to differences in incidence and 
prevalence of IBD across regions.81
This systematic review has some major strengths. We had 
undertaken a comprehensive search including important on-
line databases (Medline, Embase, Web of Science, and Co-
chrane Library). We had no language or publication restric-
tions. Moreover, relevant conference proceedings were 
searched since 2005 to ensure no publication bias was intro-
duced within our search. We excluded studies that were 
merely restricted to SB-CD since we also needed information 
from the LB in order to compare. We excluded those studies 
solely describing postoperative cohorts to exclude the effect of 
non-IBD related anastomotic ulceration on the analysis. 
Moreover, since the raw figures (i.e., TP, TN, FP and FN in both 
SB and LB locations) of the selected studies were not provided 
in the original published manuscripts, electronic communica-
tion with relevant study authors was undertaken as part of our 
data extraction process for this systematic review. 
The range of sensitivities and specificities for FC by disease 
location are variable and incomparable. As the gold standard 
comparators used in various studies are heterogeneous it has 
not been possible to pool the data and calculate common 
variables for FC. Prospective cohort studies with common 
comparators and similar quantification methodologies for FC 
are needed to answer this question; in order to better under-
stand the right place for FC as a disease monitoring tool. 
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Supplementary Material 1
Search strategies:
A. Medline - Search strategy
1. exp Leukocyte L1 Antigen Complex/
2. (calprotectin* or calgranulin*).mp. 
3. (S100A8* or S100A9*).mp. 
4. "Leukocyte L1 Antigen Complex".mp. 
5. (leu#ocyt* adj3 “L1” adj3 antigen* adj3 complex*).mp. 
6. 1 or 2 or 3 or 4 or 5
7. exp Biological Markers/
8. ((( bio* or lab* or progno* or predict* or fecal* or faecal* or feces* or faeces*) adj2 marker*) or biomarker* or (biologic* adj 
marker*) or marker* or surrogat*).mp.
9. 7 or 8
10. exp Crohn Disease/
11. crohn*.mp. 
12. exp Inflammatory Bowel Diseases/
13. (ibd* or (inflam* adj3 bowel*)).mp. 
14. exp Colitis, Ulcerative/
15. (ulcer* adj3 colitis*).mp. 
16. 10 or 11 or 12 or 13 or 14 or 15
17. (fecal* or faecal* or feces* or faeces* or excret* or stool*).mp.
18. 6 and 16
19. 9 and 16 and 17
20. 18 or 19
B. Embase - Search strategy
1. exp calgranulin/
2. (calprotectin* or calgranulin*).mp. 
3. "Leukocyte L1 Antigen Complex".mp.
4. (leu#ocyt* adj3 “L1” adj3 antigen* adj3 complex*).mp.
5. (S100A8* or S100A9*).mp.
6. 1 or 2 or 3 or 4 or 5
7. exp biological marker/
8. ((( bio* or lab* or progno* or predict* or fecal* or faecal* or feces* or faeces*) adj2 marker*) or biomarker* or (biologic* adj 
marker*) or surrogat*).mp. 
9. 7 or 8
10. exp Crohn disease/
11. exp ulcerative colitis/
12. exp inflammatory bowel disease/
13. crohn*.mp.
14. (ibd* or (inflam* adj3 bowel*)).mp.
15. (ulcer* adj3 colitis*).mp.
16. 10 or 11 or 12 or 13 or 14 or 15
See “Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn’s 
disease? - a systematic review” on page 1-11.
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17. (faecal* or fecal* or feces* or faeces* or stool* or excre*).mp. 
18. 6 and 16
19. 9 and 16 and 17
20. 18 or 19
C. Cochrane Library (Central) - Search strategy
1. “Inflammatory bowel disease” or “ulcerative colitis” or “Crohn’s disease”
2. “disease activity”
3. “calprotectin”
4. (1 OR 2) AND 3
D. Web of Science - Search strategy
1. “Inflammatory bowel disease” or “ulcerative colitis” or “Crohn’s disease”
2. “calprotectin” or “calgranulin”
3. 1 AND 2
Supplementary Material 2
The following criteria were assessed in QUADAS-2:
1. Was a consecutive or random sample of subjects enrolled?
2. Was a case-control design avoided?
3. Did the study avoid inappropriate exclusions?
4. Could the selection of subjects have introduced bias?
5. Is there concern that the included subjects do not match the review question?
6. Were the index test results interpreted without knowledge of the results of the reference standard?
7. If a threshold was used, was it pre-specified?
8. Could the conduct or interpretation of the index test have introduced bias?
9. Is there concern that the index test, its conduct, or interpretation differ from the review question?
10. Is the reference standard likely to correctly classify the target condition?
11. Were the reference standard results interpreted without knowledge of the results of the index test?
12. Could the reference standard, its conduct, or its interpretation have introduced bias?
13. Is there concern that the target condition as defined by the reference standard does not match the review question?
14. Was there an appropriate interval between index test (s) and reference standard?
15. Did all subjects receive a reference standard?
16. Did subjects receive the same reference standard?
17. Were all subjects included in the analysis?
18. Could the subject flow have introduced bias?
We modified the application of the QUADAS-2 as previously shown.1 With regard to question 5, “low concern” was scored if the 
subjects clearly had established CD and “high concern” if the study sample had subjects presenting for the first time with CD. 
Question 6 was not scored as fecal calprotectin is an objective test based on laboratory result which is not affected by blinding 
the index test interpreter to the reference standard. The applicability of the index test (question 9) was not a concern for this re-
view despite the variations in the way the index test was performed and interpreted. For question 10, “yes” was scored for all the 
studies since endoscopy is considered the gold standard for diagnosis of CD while MRI or CT are considered useful in assess-
ment for CD in the small bowel in the most recent European guidelines.2,3 Since the gold standards used for assessment of CD 
were endoscopy, MRI or CT; question 13 (applicability of reference standard) was considered not of concern.
 The responses for the signalling questions were “yes,” “no” or “unclear” and the risk of bias was marked as “low,” “high” or “un-
clear.” If all the signalling questions for a particular domain were “yes,” this would indicate a “low” risk of bias while presence of 
any “no” would raise the concern for bias. When the information was insufficient, “unclear” has been marked.
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